Q&A: Forbion Capital Partners' Sander Slootweg
Life-sciences-focused venture firm Forbion Capital Partners recently held a €360m final close for its fourth flagship fund, surpassing its initial hard-cap of €350m. Managing partner Sander Slootweg speaks to Francesca Veronesi about the fundraising process, the firm's 'build' strategy and the European life sciences venture market
More on Benelux
Seventure, BioGeneration lead €18.5m round for Citryll
Pharma company has so far raised €33.5m from private backers
M&A wave incoming in 2021, says Edmond de Rothschild CIO
Investment bank's H2 2020 outlook also emphasises continuing macroeconomic uncertainty, and singles out healthcare and data assets as winners
Committed Capital invests in MR Marine Group
Deal is the second from the GP's €55m third fund, which held a final close in January 2020
Unigestion announces closes for Secondary V and Direct II
Secondary V has held a first close on €228m, while Direct II held a third close on €375m
Latest News
Triton's Eqos Energie bolts on AML Elektrotechnik
Austria-based electrical engineering company had filed for insolvency in April 2020
Aldea Ventures launches €150m fund-of-funds
VC house expects to hold a €35-45m first close by the end of July and a final close in around one year
17Capital provides £125m in preferred equity to Exponent III
LPs in Exponent III include Aberdeen Standard Investments, Central Pension Fund and CNP Assurances
NewAlpha acquires majority stake in CHR Numerique
Company has generated €12m in revenues and has a 25% EBITDA margin